Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 386

1.

Intensive glycaemic control in type 2 diabetes mellitus: does it improve cardiovascular outcomes?

Reddy SV, Bhatia E.

Natl Med J India. 2011 Jan-Feb;24(1):21-7. Review.

PMID:
21608354
2.

Early and intensive therapy for management of hyperglycemia and cardiovascular risk factors in patients with type 2 diabetes.

Dailey G.

Clin Ther. 2011 Jun;33(6):665-78. doi: 10.1016/j.clinthera.2011.04.025. Review.

PMID:
21704233
3.

Systematic review on urine albumin testing for early detection of diabetic complications.

Newman DJ, Mattock MB, Dawnay AB, Kerry S, McGuire A, Yaqoob M, Hitman GA, Hawke C.

Health Technol Assess. 2005 Aug;9(30):iii-vi, xiii-163. Review.

4.

Lipoprotein abnormalities and their consequences for patients with type 2 diabetes.

Krentz AJ.

Diabetes Obes Metab. 2003 Nov;5 Suppl 1:S19-27. Review.

PMID:
14984018
5.

Veterans Affairs Cooperative Study on glycemic control and complications in type II diabetes (VA CSDM). Results of the feasibility trial. Veterans Affairs Cooperative Study in Type II Diabetes.

Abraira C, Colwell JA, Nuttall FQ, Sawin CT, Nagel NJ, Comstock JP, Emanuele NV, Levin SR, Henderson W, Lee HS.

Diabetes Care. 1995 Aug;18(8):1113-23.

PMID:
7587846
6.

Intensive statin therapy for Indians: Part-I. Benefits.

Enas EA, Pazhoor HC, Kuruvila A, Vijayaraghavan K.

Indian Heart J. 2011 May-Jun;63(3):211-27. Review.

PMID:
22734339
7.

Intensive glycemic control and cardiovascular disease: are there patients who may benefit?

Chokrungvaranon N, Deer J, Reaven PD.

Postgrad Med. 2011 Nov;123(6):114-23. doi: 10.3810/pgm.2011.11.2501. Review.

PMID:
22104460
8.

Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial: design and methods.

ACCORD Study Group, Buse JB, Bigger JT, Byington RP, Cooper LS, Cushman WC, Friedewald WT, Genuth S, Gerstein HC, Ginsberg HN, Goff DC Jr, Grimm RH Jr, Margolis KL, Probstfield JL, Simons-Morton DG, Sullivan MD.

Am J Cardiol. 2007 Jun 18;99(12A):21i-33i. Epub 2007 Apr 16.

PMID:
17599422
10.

Diabetes and obesity: therapeutic targeting and risk reduction - a complex interplay.

Niswender K.

Diabetes Obes Metab. 2010 Apr;12(4):267-87. doi: 10.1111/j.1463-1326.2009.01175.x. Review.

PMID:
20380648
11.

Independent contribution of A1C, systolic blood pressure, and LDL cholesterol control to risk of cardiovascular disease hospitalizations in type 2 diabetes: an observational cohort study.

Nichols GA, Joshua-Gotlib S, Parasuraman S.

J Gen Intern Med. 2013 May;28(5):691-7. doi: 10.1007/s11606-012-2320-1. Epub 2013 Jan 24.

12.

Intensive glucose control and cardiovascular outcomes in type 2 diabetes.

Macisaac RJ, Jerums G.

Heart Lung Circ. 2011 Oct;20(10):647-54. doi: 10.1016/j.hlc.2010.07.013. Epub 2010 Aug 31. Review.

PMID:
20807681
13.

Design of the cooperative study on glycemic control and complications in diabetes mellitus type 2: Veterans Affairs Diabetes Trial.

Abraira C, Duckworth W, McCarren M, Emanuele N, Arca D, Reda D, Henderson W; VA Cooperative Study of Glycemic Control and Complications in Diabetes Mellitus Type 2.

J Diabetes Complications. 2003 Nov-Dec;17(6):314-22.

PMID:
14583175
14.

Treating diabetes today with gliclazide MR: a matter of numbers.

Avogaro A.

Diabetes Obes Metab. 2012 Jan;14 Suppl 1:14-9. doi: 10.1111/j.1463-1326.2011.01508.x. Review.

PMID:
22118706
15.

Pharmacologic prevention of microvascular and macrovascular complications in diabetes mellitus: implications of the results of recent clinical trials in type 2 diabetes.

Tandon N, Ali MK, Narayan KM.

Am J Cardiovasc Drugs. 2012 Feb 1;12(1):7-22. doi: 10.2165/11594650-000000000-00000. Review.

PMID:
22217193
16.

Insulin glargine provides greater improvements in glycaemic control vs. intensifying lifestyle management for people with type 2 diabetes treated with OADs and 7-8% A1c levels. The TULIP study.

Blicklé JF, Hancu N, Piletic M, Profozic V, Shestakova M, Dain MP, Jacqueminet S, Grimaldi A.

Diabetes Obes Metab. 2009 Apr;11(4):379-86. doi: 10.1111/j.1463-1326.2008.00980.x. Epub 2008 Dec 14.

PMID:
19087105
17.

What matters in ADVANCE and ADVANCE-ON.

Hamet P.

Diabetes Obes Metab. 2012 Jan;14 Suppl 1:20-9. doi: 10.1111/j.1463-1326.2011.01509.x. Review.

PMID:
22118707
18.

Pre-existing cardiovascular diseases and glycemic control in patients with type 2 diabetes mellitus in Europe: a matched cohort study.

Fu AZ, Qiu Y, Radican L, Yin DD, Mavros P.

Cardiovasc Diabetol. 2010 Apr 21;9:15. doi: 10.1186/1475-2840-9-15.

19.
20.

Interim analysis of the effects of exenatide treatment on A1C, weight and cardiovascular risk factors over 82 weeks in 314 overweight patients with type 2 diabetes.

Blonde L, Klein EJ, Han J, Zhang B, Mac SM, Poon TH, Taylor KL, Trautmann ME, Kim DD, Kendall DM.

Diabetes Obes Metab. 2006 Jul;8(4):436-47.

PMID:
16776751

Supplemental Content

Support Center